https://scholars.lib.ntu.edu.tw/handle/123456789/558052
標題: | Randomized study of benidipine versus lercanidipine therapy in patients with mild to moderate hypertension | 作者: | CHO-KAI WU DING-CHENG CHAN Wang, Kang Ling Yu, Wen Chung HAO-HSIANG CHANG Shyu, Kou Gi Hung,Cheng Yu Tzeng, Bing Hsiean Cheng, Shu Meng HWANG, JUEY-JEN |
關鍵字: | Benidipine | Hypertension | Lercanidipine | 公開日期: | 1-十月-2020 | 卷: | 31 | 期: | 5 | 來源出版物: | Journal of Internal Medicine of Taiwan | 摘要: | The calcium channel blocker (CCB) benidipine is used as a first-line antihypertensive agent in hypertension. This multicenter, randomized, double-blind, double-dummy, lercanidipine-controlled trial aimed to evaluate the efficacy and safety of benidipine 4 mg in 178 patients with essential hypertension in Taiwan. After a 4-week treatment, mean change in systolic blood pressure (SBP) was -14.07 mmHg [95% confidence interval [CI]: -17.07 to -11.08] and -11.55 mmHg [95% CI: -14.24 to -8.86] in the benidipine and lercanidipine arms, respectively. Since the upper limit of the 95% CI (1.59) of the adjusted group difference in mean change of SBP at week 4 was less than 4.5 mmHg, benidipine could be considered non-inferior to lercanidipine based on the per protocol population. The diastolic BP was reduced by -5.81 mmHg (95% CI: -7.67 to -3.94) and -5.56 mmHg (95% CI: -7.14 to -3.99) in the benidipine and lercanidipine arms, respectively, after a 4-week treatment; no significant difference was noted (p = 0.9856). The BP target (< 140/90 mmHg) achievement showed no significant difference (p = 0.4087) or intervention advantage (odds ratio [OR] = 1.38,95% CI: 0.64-2.95) in proportion of responders between groups. In total, 13 and 14 subjects in the benidipine and lercanidipine groups, respectively, experienced study drug-related adverse events (AEs), consistent with expected side effects. No serious AEs or deaths occurred during the study. In conclusion, benidipine 4 mg could be considered non-inferior to lercanidipine 10 mg after 4 weeks of antihypertensive treatment with an acceptable tolerability profile. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/558052 | ISSN: | 10167390 | DOI: | 10.6314/JIMT.202010_31(5).07 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。